Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Shares Issued (2016 - 2024)

Aptevo Therapeutics' Shares Issued history spans 9 years, with the latest figure at -$4.2 million for Q4 2024.

  • For Q4 2024, Shares Issued fell 390.74% year-over-year to -$4.2 million; the TTM value through Dec 2024 reached $2.6 million, down 16.08%, while the annual FY2024 figure was $5.6 million, 82.57% up from the prior year.
  • Shares Issued for Q4 2024 was -$4.2 million at Aptevo Therapeutics, down from $5.8 million in the prior quarter.
  • Across five years, Shares Issued topped out at $21.2 million in Q4 2020 and bottomed at -$9.2 million in Q3 2021.
  • The 5-year median for Shares Issued is $1.4 million (2023), against an average of $3.0 million.
  • The largest YoY upside for Shares Issued was 1300.83% in 2024 against a maximum downside of 390.74% in 2024.
  • A 5-year view of Shares Issued shows it stood at $21.2 million in 2020, then plummeted by 143.62% to -$9.2 million in 2021, then soared by 170.98% to $6.6 million in 2022, then plummeted by 77.96% to $1.4 million in 2023, then plummeted by 390.74% to -$4.2 million in 2024.
  • Per Business Quant, the three most recent readings for APVO's Shares Issued are -$4.2 million (Q4 2024), $5.8 million (Q3 2024), and $1.4 million (Q4 2023).